TAIPEI, Taiwan, October 23, 2025－TaiGen Biopharmaceuticals Holdings Ltd. (“TaiGen”) announces that it has signed a commercialization licensing agreement for its antiviral, Pixavir marboxil (TG-1000), with a pharmaceutical company in India. This agreement officially marks TaiGen’s entry into the South Asian pharmaceutical market as part of its global drug expansion.

Under the agreement, the India partner will lead development, regulatory approval, manufacturing, and commercialization in the territory. TaiGen will receive upfront payment, milestone payments, and sales-based royalties, reflecting the value of its innovative therapy and supporting ongoing R&D.

Kuo-Lung Huang, Chairman of TaiGen, said, “This collaboration reflects TaiGen’s commitment to advancing innovative medicines that address unmet medical needs. With the India partner’s extensive market presence, our new therapy will offer patients in India an important treatment option while accelerating the global reach of TaiGen’s innovations.”

India has faced mounting public health pressures, with rising rates of non-communicable diseases alongside persistent infectious disease challenges, creating sustained demand for anti-infective medicines. In light of the competitive nature of the pharmaceutical market and commercial confidentiality, the India partner’s name is not being disclosed at this time.

About TaiGen Biotechnology Co. Ltd.
Founded in 2001 and listed on the Taiwan OTC Market in 2014, TaiGen Biotechnology is a fully integrated pharmaceutical company focused on innovative small-molecule drugs, particularly anti-infectives. The company has expertise in drug discovery, development, regulatory approval, and multi-country clinical trials, with experience in overseas licensing. Its flagship antibiotic, Taigexyn® (Nemonoxacin), is approved in Taiwan, China, and Russia, while the antiviral TG-1000 has completed Phase III trials and filed an NDA in China.